Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience

Brigida Santos, MD, Maria Nakafeero, Adam Lane, PhD, Leon Tshilolo, MDPhD, Thomas N. Williams, MDPhD, Peter Olupot-Olupot, MDPhD, Janet Adams, Banu Aygun, MD, Susan E. Stuber, MA, George A. Tomlinson, PhD BSc, MSc, Teresa Latham, MA, Patrick T. McGann, MD MS, Russell E. Ware, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142318

Published: 2020

Journal Articles

Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience

Banu Aygun, MD, George A. Tomlinson, PhD BSc, MSc, Patrick T. McGann, MD MS, Leon Tshilolo, MDPhD, Thomas N. Williams, MDPhD, Peter Olupot-Olupot, MDPhD, Brigida Santos, MD, Susan E. Stuber, MA, Adam Lane, PhD, Teresa Latham, MA, Russell E. Ware, MD PhD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-134180

Published: 2020

Journal Articles

Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-143139

Published: 2020

Journal Articles

Mental Health Assessment of Youth with Sickle Cell Disease and Their Primary Caretakers: Baseline Depression and COVID-19 Pandemic-Associated Psychosocial Stress in a Multi-Site Study

Nancy S. Green, MD, Deepa Manwani, MD, Kim Smith-Whitley, MD, Banu Aygun, MD, Abena Appiah-Kubi, MD MPH, Arlene Smaldone, PhD CPNP

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-140866

Published: 2020

Journal Articles

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Alexis A. Thompson, MD, Mark C. Walters, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Banu Aygun, MD, Kimberly A. Kasow, DO, Stacey Rifkin-Zenenberg, DO, Manfred Schmidt, PhD, Jay DelCarpini, Francis J. Pierciey, Jr., Alexandra L. Miller, Meghan E. Gallagher, MSc, Ren Chen, Sunita Goyal, MD, Julie Kanter, MD, John F. Tisdale, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134940

Published: 2020

Journal Articles

Benefit and Safety of Isovolemic Hemodilution Prior to Red Cell Exchange in Chronically Transfused Sickle Cell Patients

Katayoun Fomani, MD, Cindy Xu, Swathi Ratkal, MD, Vijay Nandi, PhD, Abena Appiah-Kubi, MD MPH, Banu Aygun, MD, James Louie, MD, Patricia Shi, MD

Blood (2019) 134 (Supplement_1): 2291.

https://doi.org/10.1182/blood-2019-122259

Published: 2019

Journal Articles

Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa

Peter Olupot-Olupot, George A. Tomlinson, PhD BSc, MSc, Teresa S. Latham, MA, Patrick T. McGann, MD, Brigida Santos, Banu Aygun, MD, Susan Stuber, MA, Leon Tshilolo, MD PhD, Adam Lane, PhD, Thomas N. Williams, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 522.

https://doi.org/10.1182/blood-2019-129251

Published: 2019

Journal Articles

Splenomegaly in Children with Sickle Cell Anemia Receiving Hydroxyurea in Sub-Saharan Africa

Leon Tshilolo, MD PhD, George A. Tomlinson, PhD BSc, MSc, Patrick T. McGann, MD, Teresa S. Latham, MA, Peter Olupot-Olupot, Brigida Santos, Banu Aygun, MD, Susan Stuber, MA, Adam Lane, PhD, Thomas N. Williams, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 993.

https://doi.org/10.1182/blood-2019-129937

Published: 2019

Journal Articles

Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa

Leon Tshilolo, MDPhD, George Tomlinson, Thomas N. Williams, Brigida Santos, Peter Olupot-Olupot, Adam Lane, PhD, Banu Aygun, MD, Susan Stuber, MA, Teresa Latham, MA, Patrick T. McGann, MD, Russell E. Ware, MD PhD

Blood (2018) 132 (Supplement 1): 3.

https://doi.org/10.1182/blood-2018-99-113818

Published: 2018

Journal Articles

Comparison of Impulse Oscillometry with Spirometry to Assess Lung Function in Children with Sickle Cell Disease (SCD)

Nnenna R Ukachi, MBBS, Elizabeth K Fiorino, MD, Martin Lesser, PhD, Karalyn Pappas, Abena Appiah-Kubi, MD MPH, Donna Brower, MSN, CPNP, Maria Teresa Santiago, MD, Banu Aygun, MD

Blood (2017) 130 (Supplement 1): 2247.

https://doi.org/10.1182/blood.V130.Suppl_1.2247.2247

Published: 2017

Journal Articles

Iron Unloading By Therapeutic Phlebotomy in Previously Transfused Children with Sickle Cell Anemia: The Twitch Experience

Banu Aygun, MD, Nicole Mortier, PA-C, Zora R. Rogers, MD, William Owen, MD, Beng Fuh, MD, Alex George, MD, PhD, Theodosia A. Kalfa, MD PhD, Janet Kwiatkowski, MD, Margaret Lee, MD, Hamayun Imran, MD, Scott T. Miller, MD, John C Wood, MD PhD, Alan R. Cohen, MD, Sara L Pressel, MS, Russell E. Ware, MD PhD

Blood (2016) 128 (22): 1018.

https://doi.org/10.1182/blood.V128.22.1018.1018

Published: 2016

Journal Articles

Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial

Russell E. Ware, MD PhD, Adam Lane, PhD, William H Schultz, MHS PA, Hamayun Imran, MD, Margaret T. Lee, MD, Matthew M Heeney, MD, Clark Brown, MD PhD, Lori Luchtman-Jones, MD, Jennifer Webb, MD, Sherron Jackson, MD, Banu Aygun, MD, Scott T. Miller, MD, Jennifer A Rothman, MD, Alexis A. Thompson, MD MPH, Judy Luden, CCRP, Barry R Davis, MD PhD, Robert J. Adams, MD

Blood (2016) 128 (22): 1019.

https://doi.org/10.1182/blood.V128.22.1019.1019

Published: 2016

Journal Articles

Agreement Between R2 and R2* Liver Iron Estimates Is Independent of the Type of Iron Removal Therapy: Results from the Twitch Trial

John C Wood, MD PhD, Tim St Pierre, PhD, Banu Aygun, MD, Nicole Mortier, PA-C, William H Schultz, MHS PA, Connie M. Piccone, MD, Jane Hankins, MD MS, Zora R. Rogers, MD, William Owen, MD, Isaac Odame, MBChB, FRCPath, FRCPC, Sharada A. Sarnaik, MD, Lee Hilliard, MD, Alan R. Cohen, MD, Russell E. Ware, MD PhD

Blood (2016) 128 (22): 1274.

https://doi.org/10.1182/blood.V128.22.1274.1274

Published: 2016

Journal Articles

Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia

Beverly A Schaefer, MD, Jonathan M Flanagan, PhD, Banu Aygun, MD, Ofelia A. Alvarez, MD, Stephen C Nelson, MD, Kerri A Nottage, MD MPH, Carla W Roberts, MD, Thad A. Howard, MS, Barry R Davis, MDPhD, Russell E. Ware, MD PhD

Blood (2015) 126 (23): 3393.

https://doi.org/10.1182/blood.V126.23.3393.3393

Published: 2015

Journal Articles

TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia

Russell E. Ware, MD PhD, Barry R Davis, MD PhD, William H Schultz, MHS PA, Clark Brown, MD PhD, Banu Aygun, MD, Sharada A. Sarnaik, MD, Isaac Odame, MD, Beng Fuh, MD, Alex George, MD, PhD, William Owen, MD, Lori Luchtman-Jones, MD, Zora R. Rogers, MD, Lee Hilliard, MD, Cynthia Gauger, MD, Connie M. Piccone, MD, Margaret T. Lee, MD, Janet Kwiatkowski, MD, Sherron Jackson, MD, Scott T. Miller, MD, Carla W Roberts, MD, Matthew M. Heeney, MD FRCP(C), Theodosia A. Kalfa, MD PhD, Stephen C Nelson, MD, Hamayun Imran, MD, Kerri A Nottage, MD MPH, Ofelia A. Alvarez, MD, Melissa Rhodes, MD, Alexis A. Thompson, MD, Jennifer Rothman, MD, Kathleen J. Helton, MD, Donna Roberts, MD, Jamie Coleman, MD, Melanie J Bonner, PhD, Abdullah Kutlar, MD, Niren Patel, MD, John C Wood, MD PhD, Linda Piller, MD, Peng Wei, PhD, Judy Luden, CCRP, Nicole A. Mortier, MHS, PA-C, Susan Stuber, MA, Naomi L.C. Luban, MD, Alan R. Cohen, MD, Sara L Pressel, MS, Robert J. Adams, MD MS

Blood (2015) 126 (23): 3.

https://doi.org/10.1182/blood.V126.23.3.3

Published: 2015

Journal Articles

Brain MRI/MRA Findings after Hydroxyurea Treatment in Children with Sickle Cell Anemia

Kerri Nottage, MD MPH, Russell E. Ware, MD PhD, Matthew P. Smeltzer, MStat, PhD, Jola Dowdy, MS, Winfred C. Wang, MD, Jane S. Hankins, MD MS, Kathleen J. Helton, MD, Banu Aygun, MD

Blood (2014) 124 (21): 89.

https://doi.org/10.1182/blood.V124.21.89.89

Published: 2014

Journal Articles

Higher Fetal Hemoglobin Following Escalation of Hydroxyurea to Maximum Tolerated Dose Provides Clinical Benefit to Children with Sickle Cell Anemia

Jeremie H. Estepp, MD, Matthew P. Smeltzer, MStat, PhD, Guolian Kang, PhD, Banu Aygun, MD, Russell E. Ware, MD, PhD, Kerri Nottage, MD MPH

Blood (2014) 124 (21): 85.

https://doi.org/10.1182/blood.V124.21.85.85

Published: 2014

Journal Articles

Effects of Chronic Transfusion Therapy on transcranial Doppler Ultrasonography Velocities in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Findings from the Twitch Trial

Hamayun Imran, MD MSc, Banu Aygun, MD, Barry R. Davis, MD PhD, Sara L. Pressel, MS, William Herbert Schultz, PA-C, Sherron M. Jackson, MD, Sharon A. Singh, MD, Sharada A. Sarnaik, MD, Cynthia A. Gauger, MD, Beng Fuh, MD, Kathleen J. Helton, MD, Donna Roberts, MD, Robert J. Adams, MD MS, Russell E. Ware, MD, PhD

Blood (2014) 124 (21): 87.

https://doi.org/10.1182/blood.V124.21.87.87

Published: 2014

Journal Articles

High Failure Rate with Brigance Developmental Screening in 3 Year-Old Children with Sickle Cell Disease

Winfred C. Wang, MD, Molly Beth Freeman, MS, Yvonne M. Carroll, JD, RN, Latacha Hamilton, EdS, Matthew P. Smeltzer, MStat, PhD, Guolian Kang, PhD, Jane S. Hankins, MD MS, Banu Aygun, MD

Blood (2014) 124 (21): 4926.

https://doi.org/10.1182/blood.V124.21.4926.4926

Published: 2014

Journal Articles

Hydroxyurea Pharmacokinetics for Predicting Maximum Tolerated Dose in Children with Sickle Cell Anemia

Patrick T. McGann, MDMS, Alex Sparreboom, PhD, Nicole A Mortier, MHS, PA-C, Banu Aygun, MD, Thad A Howard, MS, Kerri Nottage, MD MPH, Russell E. Ware, MD PhD

Blood (2014) 124 (21): 2707.

https://doi.org/10.1182/blood.V124.21.2707.2707

Published: 2014

NARROW

Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience

Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience

Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment

Mental Health Assessment of Youth with Sickle Cell Disease and Their Primary Caretakers: Baseline Depression and COVID-19 Pandemic-Associated Psychosocial Stress in a Multi-Site Study

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Benefit and Safety of Isovolemic Hemodilution Prior to Red Cell Exchange in Chronically Transfused Sickle Cell Patients

Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa

Splenomegaly in Children with Sickle Cell Anemia Receiving Hydroxyurea in Sub-Saharan Africa

Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa

Comparison of Impulse Oscillometry with Spirometry to Assess Lung Function in Children with Sickle Cell Disease (SCD)

Iron Unloading By Therapeutic Phlebotomy in Previously Transfused Children with Sickle Cell Anemia: The Twitch Experience

Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial

Agreement Between R2 and R2* Liver Iron Estimates Is Independent of the Type of Iron Removal Therapy: Results from the Twitch Trial

Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia

TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia

Brain MRI/MRA Findings after Hydroxyurea Treatment in Children with Sickle Cell Anemia

Higher Fetal Hemoglobin Following Escalation of Hydroxyurea to Maximum Tolerated Dose Provides Clinical Benefit to Children with Sickle Cell Anemia

Effects of Chronic Transfusion Therapy on transcranial Doppler Ultrasonography Velocities in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Findings from the Twitch Trial

High Failure Rate with Brigance Developmental Screening in 3 Year-Old Children with Sickle Cell Disease

Hydroxyurea Pharmacokinetics for Predicting Maximum Tolerated Dose in Children with Sickle Cell Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only